| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Care |
Sports Medicine Research Unit (K.H.W.L., N.B., F.I., M.K.), Bispebjerg Hospital, DK-2400 Copenhagen NV, Denmark; Copenhagen Muscle Research Centre (K.H.W.L., J.L.A.), Department of Molecular Muscle Biology, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark; Team Danmark Test Center (B.L.), Bispebjerg Hospital, DK-2400 Copenhagen NV, Denmark; Clinical Drug Development (M.H.R.), Novo Nordisk, DK-2880 Bagsvaerd, Denmark; Department of Growth and Reproduction (A.J.), Rigshospitalet, DK-2100 Copenhagen Ø, Denmark; and Department of Clinical Physiology (J.B.), Bispebjerg Hospital, DK-2400, Copenhagen NV, Denmark
Address all correspondence and requests for reprints to: Kai H. W. Lange, M.D., Sports Medicine Research Unit, Building 8, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark. E-mail: klange{at}dadlnet.dk
Abstract
GH administration, either alone or combined with resistance exercise training (RT), has attracted interest as a means of increasing muscle mass and strength in the elderly. In the present study, 31 healthy, elderly men [age, 74 ± 1 yr (mean ± SEM)] were assigned to either RT [3 sessions/wk, 35 sets of 812 repetition maximum (RM)/session] + placebo (n = 8), RT + GH (n = 8), GH (n = 8), or placebo (n = 7) in a randomized, placebo-controlled, double-blinded (RT + placebo and RT + GH) or single-blinded (GH or placebo) design. Measurements of: 1) isokinetic quadriceps muscle strength; 2) quadriceps muscle power; 3) quadriceps muscle fiber type, size, and myosin heavy chain (MHC) composition; 4) quadriceps cross-sectional area (CSA) [nuclear magnetic resonance imaging (NMRI)]; 5) body composition (dual-energy x-ray absorptiometry scanning); and 6) GH-related serum markers were performed at baseline and after 12 wk. The final GH dose was 1.77 ± 0.18 IU·d-1 (
7.2 ± 0.8 µg·kg-1·d-1). GH alone had no effect on isokinetic quadriceps muscle strength, power, CSA, or fiber size. However, a substantial increase in MHC 2X isoform was observed with GH administration alone, and this may be regarded as a change into a more youthful MHC composition, possibly induced by the rejuvenating of systemic IGF-I levels. RT + placebo caused substantial increases in quadriceps isokinetic strength, power, and CSA; but these RT induced improvements were not further augmented by additional GH administration. In the RT + GH group, there was a significant decrease in MHC 1 and 2X isoforms, whereas MHC 2A increased. RT, therefore, seems to overrule the changes in MHC composition induced by GH administration alone. Changes in body composition confirmed previous reports of decreased fat mass, increased fat-free mass, and unchanged bone mineral content with GH administration. A high incidence of side effects was reported. Our results do not support a role for GH as a means of increasing muscle strength or mass, either alone or combined with RT, in healthy elderly men; although GH administration alone may induce changes in MHC composition.
This article has been cited by other articles:
![]() |
T. Munzer, S. M. Harman, J. D. Sorkin, and M. R. Blackman Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3833 - 3841. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Freda, W. Shen, C. M. Reyes-Vidal, E. B. Geer, F. Arias-Mendoza, D. Gallagher, and S. B. Heymsfield Skeletal Muscle Mass in Acromegaly Assessed by Magnetic Resonance Imaging and Dual-Photon X-Ray Absorptiometry J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2880 - 2886. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Marzetti, L. Groban, S. E. Wohlgemuth, H. A. Lees, M. Lin, H. Jobe, S. Giovannini, C. Leeuwenburgh, and C. S. Carter Effects of short-term GH supplementation and treadmill exercise training on physical performance and skeletal muscle apoptosis in old rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R558 - R567. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Bamman, J. K. Petrella, J.-s. Kim, D. L. Mayhew, and J. M. Cross Cluster analysis tests the importance of myogenic gene expression during myofiber hypertrophy in humans J Appl Physiol, June 1, 2007; 102(6): 2232 - 2239. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Suetta, P. Aagaard, S. P. Magnusson, L. L. Andersen, S. Sipila, A. Rosted, A. K. Jakobsen, B. Duus, and M. Kjaer Muscle size, neuromuscular activation, and rapid force characteristics in elderly men and women: effects of unilateral long-term disuse due to hip-osteoarthritis J Appl Physiol, March 1, 2007; 102(3): 942 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, D. M. Bravata, I. Olkin, S. Nayak, B. Roberts, A. M. Garber, and A. R. Hoffman Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly Ann Intern Med, January 16, 2007; 146(2): 104 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Solomon and P M G Bouloux Modifying muscle mass - the endocrine perspective. J. Endocrinol., November 1, 2006; 191(2): 349 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Franco, G. Johannsson, B.-A. Bengtsson, and J. Svensson Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4408 - 4414. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Perls, N. R. Reisman, and S. J. Olshansky Provision or Distribution of Growth Hormone for "Antiaging": Clinical and Legal Issues JAMA, October 26, 2005; 294(16): 2086 - 2090. [Full Text] [PDF] |
||||
![]() |
M. Hameed, K. H. W. Lange, J. L. Andersen, P. Schjerling, M. Kjaer, S. D. R. Harridge, and G. Goldspink The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men J. Physiol., February 15, 2004; 555(1): 231 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, D. R. Plant, P. Gregorevic, M. N. Sillence, and G. S. Lynch {beta}2-Agonist administration reverses muscle wasting and improves muscle function in aged rats J. Physiol., February 15, 2004; 555(1): 175 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Albert and A. D. Mooradian Low-Dose Recombinant Human Growth Hormone as Adjuvant Therapy to Lifestyle Modifications in the Management of Obesity J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 695 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. E. Suman, S. J. Thomas, J. P. Wilkins, R. P. Mlcak, and D. N. Herndon Effect of exogenous growth hormone and exercise on lean mass and muscle function in children with burns J Appl Physiol, June 1, 2003; 94(6): 2273 - 2281. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J Rennie Claims for the anabolic effects of growth hormone: a case of the Emperor's new clothes? Br. J. Sports Med., April 1, 2003; 37(2): 100 - 105. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |